Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia.

Abstract

We describe a 55-year-old man with acute myelogenous leukemia who developed breakthrough Trichosporon asahii fungemia during 5 days of micafungin treatment. Although the patient's clinical condition improved considerably after the start of voriconazole treatment, blood culture results remained positive for T. asahii for 3 days, and fever persisted for 7 days thereafter. The patient achieved complete hematological remission, and he received successful consolidation chemotherapy without developing Trichosporon infection with the prophylactic use of voriconazole therapy. This case report illustrates that voriconazole may be useful in the treatment of disseminated T. asahii infection in neutropenic patients.

• Authors: Noboru Asada, Hidetaka Uryu, Mihoko Koseki, Masami Takeuchi, Masaru Komatsu, Kosei Matsue
• Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 43 Issue 4 Pg. e39-41 (Aug 15 2006) ISSN: 1537-6591 [Electronic] United States
• PMID: 16838224 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antifungal Agents
• Echinocandins
• Lipopeptides
• Lipoproteins
• Peptides, Cyclic
• Pyrimidines
• Triazoles
• Voriconazole
• Micafungin

Topics

• Acute Disease
• Antifungal Agents (therapeutic use)
• Aspergillosis (complications, drug therapy)
• Echinocandins
• Fungemia (drug therapy)
• Humans
• Leukemia, Myeloid (complications)
• Lipopeptides
• Lipoproteins (therapeutic use)
• Male
• Micafungin
• Middle Aged
• Mycoses (complications, drug therapy, microbiology)
• Peptides, Cyclic (therapeutic use)
• Pyrimidines (therapeutic use)
• Triazoles (therapeutic use)
• Trichosporon (isolation & purification)
• Voriconazole